2 recruiting, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
Follow DNX-2401: new trials by email Literature Review of DNX-2401 trials Research Report on DNX-2401
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors DNX-2401 - High Grade Glioma, Ependymoma | Phase 2 | Recruiting | Clinica Universidad de Navarra, Universidad de Navarra | 39 | 2026-05-12 | 2026-05-27 |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas ONC201, Radiation Therapy, Paxalisib - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 2 | Recruiting | University of California, San Francisco | 360 | 2021-10-20 | 2026-06-26 |
| Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects DNX-2401, pembrolizumab - Brain Cancer, Brain Neoplasm | Phase 2 | Completed | DNAtrix, Inc. | 49 | 2016-10-06 | 2021-07-15 |
Glioma (2) · Brain Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Disease (1) · Ependymoma (1) · Glioblastoma (1) · Gliosarcoma (1) · Neoplasms (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Nervous System Diseases (1) · Neuroectodermal Tumors (1) · Recurrence (1)
Clinica Universidad de Navarra, Universidad de Navarra (1) · DNAtrix, Inc. (1) · University of California, San Francisco (1)
Netherlands (2) · United States (2) · Australia (1) · Canada (1) · Israel (1) · New Zealand (1) · Spain (1) · Switzerland (1)
Nancy Gady, BS (1) · Sabine Mueller, MD, PhD (1)
PMID 35157764, PMID 37188783, PMID 37195023
R01NS124607 (1)